TriSalus Life Sciences Q3 2026 Results: Net Loss of $8.85M, Loss Narrows
TriSalus Life Sciences reported a net loss of $16.5 million for the nine months ended September 30, 2026, an improvement from a $29.5 million loss in the prior year period. Revenue grew to $33.2 million, while the company strengthened its balance sheet with cash and cash equivalents increasing to $41.1 million.
- Key figure
- Net loss $8.85M